Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heldin, C.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heldin, C.-H.
Stem Cells, Vol. 19, No. 4, 295-303, July 2001
© 2001 AlphaMed Press

CONCISE REVIEW

Signal Transduction: Multiple Pathways, Multiple Options for Therapy

Carl-Henrik Heldin

Ludwig Institute for Cancer Research, Biomedical Center, Uppsala, Sweden

Key Words. Growth factor • Cytokine • Receptor • Kinase • Signal transduction • Antagonist

Correspondence: Carl-Henrik Heldin, Ph.D., Ludwig Institute for Cancer Research, Box 595, Biomedical Center, S-751 24 Uppsala, Sweden. Telephone: 46-18-160401; Fax: 46-18-160420; e-mail: C-H.Heldin{at}LICR.uu.se

Many aspects of cell behavior, such as growth, motility, differentiation, and apoptosis, are regulated by signals cells receive from their environment. Such signals are important, e.g., during embryonal development, wound healing, hematopoiesis, and in the regulation of the immune response, and may come from interactions with other cells or components of the extracellular matrix, or from binding of soluble signaling molecules to specific receptors at the cell membrane. Hereby different signaling pathways are initiated inside the cell. Perturbations of such signaling pathways are seen in several types of diseases, e.g., cancer, inflammatory conditions, and atherosclerosis. Thus, antagonists of several signaling pathways have potential clinical utility. Several such compounds are currently used or are in clinical trials; others are currently being analyzed in animal models.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Pichler, J. L. Prior, G. D. Luker, and D. Piwnica-Worms
Generation of a highly inducible Gal4->Fluc universal reporter mouse for in vivo bioluminescence imaging
PNAS, October 14, 2008; 105(41): 15932 - 15937.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. S. Haneline, H. White, F.-C. Yang, S. Chen, C. Orschell, R. Kapur, and D. A. Ingram
Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo
Blood, February 15, 2006; 107(4): 1375 - 1382.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Delaval, S. Letard, H. Lelievre, V. Chevrier, L. Daviet, P. Dubreuil, and D. Birnbaum
Oncogenic Tyrosine Kinase of Malignant Hemopathy Targets the Centrosome
Cancer Res., August 15, 2005; 65(16): 7231 - 7240.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. E. Luker, M. C. P. Smith, G. D. Luker, S. T. Gammon, H. Piwnica-Worms, and D. Piwnica-Worms
Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals
PNAS, August 17, 2004; 101(33): 12288 - 12293.
[Abstract] [Full Text] [PDF]

Home page
 CROBMHome page
W. J. Grzesik and A.S. Narayanan
CEMENTUM AND PERIODONTAL WOUND HEALING AND REGENERATION
Critical Reviews in Oral Biology & Medicine, November 1, 2002; 13(6): 474 - 484.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS

Copyright © 2001 by AlphaMed Press.